Skip to main content
SpringerLink
Log in

PCSK9i therapy projected to have low budget impact in USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. HMG-CoA reductase inhibitor

  2. 2017 US dollars

Reference

  • Mallya UG, et al. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. PharmacoEconomics : 27 Nov 2017. Available from: URL: https://doi.org/10.1007/s40273-017-0590-5

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PCSK9i therapy projected to have low budget impact in USA. PharmacoEcon Outcomes News 792, 23 (2017). https://doi.org/10.1007/s40274-017-4546-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4546-y

Search

Navigation